V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
D C Montefiori, … , L A Cavacini, M R Posner
D C Montefiori, … , L A Cavacini, M R Posner
Published August 1, 1993
Citation Information: J Clin Invest. 1993;92(2):840-847. https://doi.org/10.1172/JCI116658.
View: Text | PDF
Research Article
Other pages:
840 841 842 843 844 845 846 847

Other pages:
840 841 842 843 844 845 846 847